{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:32:41Z","timestamp":1786991561589,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jbo.2023.100507","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:32:23Z","timestamp":1697243543000},"page":"100507","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The low and disproportionate utilization of antiresorptive therapy in patients with osseous metastasis"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0480-9515","authenticated-orcid":false,"given":"Amil R.","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa L.","family":"LiBrizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Wessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savyasachi C.","family":"Thakkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jbo.2023.100507_b0005","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/jnci\/djac158","article-title":"Estimation of the number of individuals living with metastatic cancer in the United States","volume":"114","author":"Gallicchio","year":"2022","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2023.100507_b0010","series-title":"Cancer Treatment & Survivorship Facts & Figures 2022\u20132024","author":"A.C. Society","year":"2022"},{"key":"10.1016\/j.jbo.2023.100507_b0015","doi-asserted-by":"crossref","unstructured":"R.E. Coleman Author's Affiliation: Academic Unit of Medical Oncology, Weston Park Hospital, Sheffield, United Kingdom Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity Clinical Cancer Research 12 20 2006 6243s 9s.","DOI":"10.1158\/1078-0432.CCR-06-0931"},{"key":"10.1016\/j.jbo.2023.100507_b0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/CMAR.S33983","article-title":"Importance of antiresorptive therapies for patients with bone metastases from solid tumors","volume":"4","author":"Talreja","year":"2012","journal-title":"Cancer Manag. Res."},{"issue":"6","key":"10.1016\/j.jbo.2023.100507_b0025","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/bcr2768","article-title":"Prevention of bone metastases and management of bone health in early breast cancer","volume":"12","author":"Gnant","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jbo.2023.100507_b0030","doi-asserted-by":"crossref","unstructured":"H. Al Farii A. Frazer L. Farahdel F. AlFayyadh R. Turcotte Bisphosphonates Versus Denosumab for Prevention of Pathological Fracture in Advanced Cancers With Bone Metastasis: A Meta-analysis of Randomized Controlled Trials J Am Acad Orthop Surg Glob Res Rev 4 8 2020 e20.00045.","DOI":"10.5435\/JAAOSGlobal-D-20-00045"},{"issue":"3","key":"10.1016\/j.jbo.2023.100507_b0035","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.spinee.2018.08.004","article-title":"Rates of osteoporosis screening and treatment following vertebral fracture","volume":"19","author":"Barton","year":"2019","journal-title":"Spine J."},{"issue":"22","key":"10.1016\/j.jbo.2023.100507_b0040","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.2106\/JBJS.22.00088","article-title":"High rates of imminent subsequent fracture after femoral neck fracture in the elderly","volume":"104","author":"Bogoch","year":"2022","journal-title":"J. Bone Joint Surg. Am."},{"issue":"3","key":"10.1016\/j.jbo.2023.100507_b0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/17453674.2013.788437","article-title":"Patient and implant survival following joint replacement because of metastatic bone disease","volume":"84","author":"S\u00f8rensen","year":"2013","journal-title":"Acta Orthop."},{"issue":"9","key":"10.1016\/j.jbo.2023.100507_b0050","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.jbo.2023.100507_b0055","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jbo.2023.100507_b0060","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/00005373-196511000-00015","article-title":"The management of pathological fractures","volume":"5","author":"Higinbotham","year":"1965","journal-title":"J. Trauma Acute Care Surg."},{"issue":"6","key":"10.1016\/j.jbo.2023.100507_b0065","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.3390\/cancers15061847","article-title":"Initiation of antiresorptive drug treatment during endocrine therapy for breast cancer\u2014A retrospective cohort study of 161,492 patients in Germany","volume":"15","author":"Gremke","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jbo.2023.100507_b0070","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jobcr.2012.11.001","article-title":"Dental complications and management of patients on bisphosphonate therapy: a review article","volume":"3","author":"Kalra","year":"2013","journal-title":"J. Oral Biol. Craniofac. Res."},{"issue":"35","key":"10.1016\/j.jbo.2023.100507_b0075","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, Double-Blind Study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.jbo.2023.100507_b0080","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1200\/JOP.18.00431","article-title":"Early Clinical and economic outcomes of prophylactic and acute pathologic fracture treatment","volume":"15","author":"Mosher","year":"2019","journal-title":"J. Oncol. Pract."},{"issue":"15","key":"10.1016\/j.jbo.2023.100507_b0085","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.3390\/cancers13153662","article-title":"Fracture risk of long bone metastases: a review of current and new decision-making tools for prophylactic surgery","volume":"13","author":"Nguy\u1ec5n","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.jbo.2023.100507_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198006","article-title":"Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: A prospective cohort study","volume":"13","author":"van Geel","year":"2018","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.jbo.2023.100507_b0095","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cam4.749","article-title":"Prevalence of hypercalcemia among cancer patients in the United States","volume":"5","author":"Gastanaga","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.jbo.2023.100507_b0100","doi-asserted-by":"crossref","unstructured":"F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, J.L. Chin, J.J. Vinholes, J.A. Goas, B. Chen, F.t.Z.A.P.C.S. Group, A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma, JNCI: J. Natl. Cancer Inst. 94(19) (2002) 1458-1468.","DOI":"10.1093\/jnci\/94.19.1458"},{"issue":"1","key":"10.1016\/j.jbo.2023.100507_b0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/1471-2474-11-145","article-title":"Bone metastases from renal cell carcinoma: patient survival after surgical treatment","volume":"11","author":"Fottner","year":"2010","journal-title":"BMC Musculoskelet. Disord."},{"issue":"3","key":"10.1016\/j.jbo.2023.100507_b0110","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/j.clgc.2022.12.010","article-title":"Effect of bisphosphonates on skeletal related events in long bone metastases of renal cell carcinoma: a systematic review","volume":"21","author":"van Broekhoven","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"issue":"13","key":"10.1016\/j.jbo.2023.100507_b0115","first-page":"4659","article-title":"An Italian survey on the use of denosumab for the management of skeletal-related events in patients with bone metastases","volume":"26","author":"Berardi","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137423000404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137423000404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:21:28Z","timestamp":1761942088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137423000404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":23,"alternative-id":["S2212137423000404"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2023.100507","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The low and disproportionate utilization of antiresorptive therapy in patients with osseous metastasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2023.100507","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100507"}}